Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

HGH (Somatropin) peptide iconHGH (Somatropin)191 residues (approx.)FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.

HGH (Somatropin)

Beginner tier: 1 IU, daily · community consensus

Growth HormoneFDA Approved
~2-4 hours SC half-life·Injection

Also known as: HGH, rhGH, recombinant human growth hormone

Rudman's 1990 trial put it on the map: 8.8% more lean mass and 14.4% less body fat after six months of injections three times a week, in 12 men over 60. Somatropin (HGH) is a 191-amino-acid recombinant protein identical to the growth hormone your pituitary gland produces. It carries FDA approval for pediatric and adult growth hormone deficiency, Turner syndrome, and HIV-associated wasting. The KIMS database tracked 15,809 adults treated for GH deficiency and found a favorable long-term safety profile [2]. Cost is the barrier. Pharma-grade runs $750 to $2,000+ per month. Anti-aging users typically settle on 1 to 2 IU daily for sleep, skin, and gradual body recomposition.

What Is HGH (Somatropin)?

The Rudman study changed how the world thinks about aging. In 1990, a six-month trial gave recombinant growth hormone to men over 60 and tracked an 8.8% increase in lean body mass with a 14.4% decrease in adipose tissue (NEJM)[1]. That single paper launched three decades of research into somatropin.

Somatropin (brand names Genotropin, Humatrope, Norditropin, Omnitrope) is a 191-amino-acid protein produced via recombinant DNA technology. It's identical to endogenous human growth hormone. Unlike secretagogues that stimulate your pituitary to release GH, somatropin is the hormone itself. Subcutaneous bioavailability runs about 70 to 80 percent on the US labels that state it. Serum levels peak about 3 to 6 hours after the injection. US labels put the subcutaneous half-life at about 2 to 4 hours, including 2.0 hours for Norditropin in healthy adults. Norditropin also gives an apparent 7 to 10 hours in GHD patients. The biological effects, mediated through IGF-1, persist 20 to 24 hours.

The FDA has approved somatropin brands for pediatric GHD, adult GHD, Turner syndrome, Prader-Willi syndrome, and HIV-associated wasting. Current labels add small-for-gestational-age and idiopathic short stature, SHOX deficiency and Noonan syndrome; each brand carries its own subset. Nutropin AQ, the brand for growth failure in chronic kidney disease, is no longer licensed. Off-label use centers on anti-aging (1 to 2 IU daily), body recomposition (2 to 4 IU), and athletic performance (4 to 6 IU). Sleep quality improvement is the first thing users notice, often within the first two weeks.

The KIMS database, tracking 15,809 GH-treated adults, confirmed neutral effects on lipids and glucose at appropriate doses and found no increased malignant cancer incidence [2]. A 2007 meta-analysis of randomized trials in healthy older adults found 2.1 kg more lean mass and 2.1 kg less fat [4]. Bone density didn't change. In a 6-month trial of 52 older men, knee and grip strength didn't improve [5]. Insulin resistance remains the side effect that demands the most monitoring.

How HGH (Somatropin) Works

Somatropin binds to the growth hormone receptor (GHR), a transmembrane receptor that sits as a preformed dimer on cell surfaces. Binding triggers a conformational change that activates Janus Kinase 2 (JAK2), a tyrosine kinase physically linked to the receptor's intracellular domain. JAK2 phosphorylates tyrosine residues on the GHR itself, creating docking sites for STAT proteins.

STAT5b is the primary downstream signal. Once recruited and phosphorylated by JAK2, STAT5b dimerizes and translocates to the nucleus. There it drives transcription of target genes. The most important product is IGF-1 (insulin-like growth factor 1), produced mainly by the liver; IGF-1 mediates most of somatropin's anabolic effects. Protein synthesis accelerates. Cell proliferation increases. Apoptosis slows.

Two additional pathways matter. The MAPK/ERK pathway promotes cell growth and differentiation. The PI3K/Akt pathway regulates glucose metabolism and cell survival, which partly explains why somatropin antagonizes insulin signaling at higher doses.

Somatropin's direct lipolytic action operates through a separate mechanism that doesn't involve IGF-1 at all. Hormone-sensitive lipase activation in adipocytes breaks down stored triglycerides. This is why fat loss, particularly visceral fat, is one of the most consistent and dose-dependent effects. The dual mechanism (IGF-1-mediated anabolism plus direct lipolysis) is what makes somatropin effective for body recomposition.

HGH (Somatropin) Benefits

  • HGH (Somatropin) benefits center on body composition, recovery, and measurable improvements in quality-of-life markers backed by clinical trial data.
  • Rudman's 1990 trial [1] showed 8.8% lean body mass increase and 14.4% fat mass decrease in 12 men over 60 after six months of GH three times a week.
  • The KIMS database followed 15,809 GH-deficient adults for a mean 5.3 years. Lipids and fasting glucose stayed neutral, and new cancers ran in line with the general population [2].
  • Sleep quality improvement is the most consistently reported early benefit across community forums; users describe deeper sleep and vivid dreams within the first one to two weeks.
  • Skin elasticity and thickness improve measurably between months three and six. Nails and hair grow noticeably faster. These collagen-mediated effects track with rising IGF-1 levels.
  • Bone mineral density gains require patience. Meaningful DEXA changes typically don't appear before 12 months of consistent therapy.
  • Workout recovery and injury healing speed are among the top reasons athletes and bodybuilders use somatropin, though a 6-month randomized trial in 52 older men found no gain in knee or grip strength [5].

HGH (Somatropin): Science vs Community Consensus

Partially Aligned
Scientific Evidence
Strong
Based on 15 key studies·FDA-approved

Strong evidence for body composition improvements (lean mass, fat loss) and bone density in GH-deficient adults.

Dosing studied: 0.15–0.3 mg/day (0.45–0.9 IU/day) start for adult GHD per the Norditropin label, raised 0.1–0.2 mg every 1–2 months; 1–4 IU/day in clinical anti-aging studies; max ~4 IU/day in most adult GHD protocols
Read the evidence (key study, limitations)

Moderate evidence for general anti-aging and wellness use in healthy older adults: a 6-month RCT in 52 men over 69 showed +4.3% lean mass / -13.1% fat mass (Papadakis 1996)[5]. Long-term safety in non-GHD populations remains unresolved. That trial found no significant gain in knee or grip strength.

Key Study

Rudman et al. NEJM 1990 (PMID 2355952): foundational 6-month controlled trial (12 treated men, 9 untreated); KIMS database 15,809 patients long-term safety (PMID 35368070); Liu 2007 meta-analysis (PMID 17227934): +2.1 kg lean mass, -2.1 kg fat in healthy older adults; Papadakis 1996 RCT (PMID 8633830): no strength gain at 6 months; Frontiers in Aging 2025 clinical review (PMID 40260058)

Limitations

Most RCTs ≤12 months in duration; anti-aging use in healthy adults lacks dedicated long-term RCTs; 2024 Swedish registry study (3,408 treated as children, 50,036 controls) found HR 1.28 for all neoplastic events, significant in males only; malignant tumors did not rise (HR 0.91); no 2024–2026 RCT specifically studying 1–2 IU/day in healthy aging adults

Community Experience
Strong
3.8/5
Based on r/PEDs, r/Peptides, r/steroids: thousands of threads

Widely trusted as the gold standard for body recomposition and anti-aging.

Community dosing: 1–2 IU/day (anti-aging/wellness); 2–4 IU/day (body recomposition); 4–6 IU/day (bodybuilding)
Read the reports (what users report 6, common issues 6)

Pharma-grade is universally respected for purity; grey market quality is the primary controversy. Anti-aging community considers 1–2 IU/day a conservative, sustainable protocol; bodybuilding community uses 4–6 IU/day with AAS.

What users report (6)
  • Improved deep sleep quality (most consistently reported, within 1–2 weeks)
  • Faster recovery from training and injuries
  • Visceral fat reduction, especially abdominal (noticeable at 8–12 weeks)
  • Skin texture and elasticity improvement (3–6 months)
  • Accelerated nail and hair growth
  • Improved sense of well-being and energy
Common issues (6)
  • Cost: #1 reason for discontinuation; pharma-grade is prohibitively expensive for long-term off-label use
  • Water retention (hands, feet): first 4–6 weeks, usually resolves with dose reduction
  • Carpal tunnel / hand tingling: most common side effect requiring dose reduction
  • Morning fasting blood glucose elevation
  • Grey market quality inconsistency: underdosing and counterfeit risk widely reported
  • Lean muscle gains at anti-aging doses (1–2 IU) are modest and slow: often described as overhyped
Partially Aligned

Science and community agree on body composition benefits (lean mass gain, fat loss). Diverge on: (1) dose thresholds: community anti-aging doses (1–2 IU) sit above the Norditropin label's adult GHD starting dose (0.45–0.9 IU) but below most trial doses; (2) indication: community uses predominantly for off-label anti-aging/performance, which FDA prohibits; (3) muscle strength: community reports improved performance but a 6-month RCT in older men found no significant strength gain (PMID 8633830).

HGH (Somatropin) Dosage Guide

CommunityCommunity use: 1-2 IU/day for anti-aging, 2-4 IU/day for body recomposition, 4-6 IU/day for bodybuilding. The Norditropin label starts adults with growth hormone deficiency at about 0.2 mg (0.6 IU) a day.Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner1 IU
DailyTrack
Moderate3 IU
DailyTrack
Aggressive6 IU
DailyTrack
Note:

Somatropin is dosed in IU, not mcg. One IU equals roughly 0.33 mg. That conversion trips people up initially.

If you're using lyophilized powder (not a ready-to-use pen), mix it with the diluent that comes with your product. Brands differ: Omnitrope's 5.8 mg vial ships with bacteriostatic water (benzyl alcohol), Zomacton 10 mg with bacteriostatic water (metacresol) and Zomacton 5 mg with bacteriostatic saline (FDA labels). For a 10 IU vial with 1 mL of diluent, each 10 units on an insulin syringe equals 1 IU. A 1 IU daily dose means drawing to the 10-unit mark. At 2 IU, draw to 20 units. At 0.5 IU for the ramp-in phase, that's 5 units on the syringe.

Pens skip this math entirely. Norditropin FlexPro comes ready-mixed, and a Genotropin cartridge is mixed inside its own pen. Dial the dose and inject.

Inject on an empty stomach. Carbohydrates blunt GH action. Morning fasted or pre-bed are the two most common timing windows. Splitting the dose (AM plus pre-bed) becomes relevant above 3 IU daily.

Store reconstituted vials at 2 to 8 degrees Celsius and never freeze them. US labels set room-temperature limits brand by brand. A Norditropin pen in use keeps 3 weeks at up to 25 degrees Celsius; mixed vials of the other brands stay refrigerated.

IGF-1 labs every three months. That's the number that tells you whether your dose is working and whether it's too high.

Cycling Protocol

On Period
24 weeks
Off Period
4 weeks

For anti-aging doses (1-2 IU), many practitioners run continuously with periodic IGF-1 monitoring rather than cycling. At higher doses (4+ IU), 6 months on / 1 month off helps maintain insulin sensitivity. Some protocols use 5 days on, 2 days off weekly to reduce cost and manage sides.

Calculate your HGH (Somatropin) dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

HGH (Somatropin) Protocols by Goal

beginnerCommunity24 weeks on, 4–8 weeks off; many practitioners run continuously at this dose with periodic IGF-1 monitoring
Ramp-in
Wk 1–4
0.5 IU · Daily · Subcutaneous
Maintenance
Wk 5–24
1–1.5 IU · Daily (or 5 days on / 2 days off to reduce cost) · Subcutaneous

Expected: Improved sleep quality (weeks 1–2), skin texture (months 2–4), mild fat redistribution (months 3–6); modest lean mass gains over 6+ months; significant muscle hypertrophy not expected at this dose

Monitor: IGF-1 at baseline and every 3 months; fasting glucose and HbA1c every 3–6 months; TSH at baseline

How to Use HGH (Somatropin)

  1. 1
    Wash hands thoroughly

    Set out your vial, the diluent supplied with it (brands differ, so check the label), alcohol swabs, and a 29 to 31 gauge insulin syringe (0.5 mL or 1 mL).

  2. 2
    Step 2

    If using a lyophilized vial for the first time, reconstitute by drawing the diluent volume your product's label gives into the syringe (the math below uses 1 mL). Inject slowly along the vial wall. Never shake the vial; swirl gently until the powder dissolves completely.

  3. 3
    Calculate your syringe units

    With a 10 IU vial reconstituted in 1 mL of diluent, each 10 units on a 100-unit insulin syringe equals 1 IU. For a 30 IU vial in 1 mL, each 3.3 units equals 1 IU; for a 36 IU vial in 1 mL, each 2.8 units equals 1 IU.

  4. 4
    Swab the vial top with alcohol

    Draw the appropriate number of units. Remove air bubbles by tapping and slowly pushing the plunger until a tiny drop appears at the needle tip.

  5. 5
    Step 5

    Choose an injection site: abdomen (2 inches from the navel), outer thigh, or upper arm. Clean the site with an alcohol swab.

  6. 6
    Step 6

    Pinch a fold of skin and insert the needle at a 45 to 90 degree angle. Inject slowly. Hold for 5 seconds before withdrawing.

  7. 7
    Step 7

    Rotate injection sites with each dose to prevent lipodystrophy.

  8. 8
    Step 8

    Timing: inject fasted (30 to 60 minutes before food) in the morning for fat loss protocols. Pre-bed injection mimics natural circadian GH release and is preferred for sleep-focused or FDA-labeled GHD protocols. Above 3 IU daily, split into AM fasted plus pre-bed.

  9. 9
    Step 9

    Store reconstituted vial in the refrigerator at 2 to 8 degrees Celsius. Use within 14 to 28 days depending on brand. Never freeze.

Alternative Routes

Subcutaneous (SC)

Reference standard; ~70–80% bioavailability on US labels. Inject into abdomen, thigh, or upper arm.

Rotate sites to prevent lipodystrophy. Peak serum GH at about 3–6 hours. Insulin syringes (29–31G) are standard. Norditropin FlexPro pens hold a ready-mixed solution; Genotropin cartridges are mixed inside the pen before first use.

Intramuscular (IM)

Peak at about 3 hours vs 4–6 hours SC, with higher total exposure (AUC 194 vs 134 ng·h/mL) in 12 healthy volunteers (PMID 1490668). No US label gives an IM dose.

Used clinically in some pediatric protocols. More painful for daily injections. No evidence of superior efficacy over SC for adult use. SC is universally preferred for self-administration.

Intravenous (IV)

Immediate but very short-lived peak; pharmacokinetically inferior for therapeutic use

IV route is used only for GH stimulation testing (GHRH + arginine test) under clinical supervision. Not appropriate for therapeutic or off-label protocols.

Mixing your own vial? Use the HGH (Somatropin) reconstitution calculator for the exact diluent-to-dose math on any vial size.

HGH (Somatropin) Stacking Protocols

Works With

Avoid

Oral estrogen (estradiol, conjugated estrogens)

Oral estrogen significantly reduces hepatic IGF-1 production in response to GH: women on oral HRT or oral contraceptives may require 2–3x higher HGH doses to achieve equivalent IGF-1 response. Transdermal estrogen has substantially less impact. Not dangerous but severely reduces efficacy.

Glucocorticoids (prednisone, hydrocortisone, dexamethasone)

Glucocorticoids attenuate GH growth-promoting effects and impair IGF-1 signaling. HGH may reduce 11β-HSD1 activity, altering cortisol conversion; in adrenal insufficiency patients on replacement therapy, HGH can unmask adrenocortical insufficiency requiring glucocorticoid dose adjustment. Monitor carefully.

Somatostatin analogs (octreotide, lanreotide, pasireotide)

Somatostatin analogs suppress GH secretion, so they blunt any GH secretagogue. They are used to block GH in acromegaly and work against HGH too (community stack guidance).

Do not combine
Insulin (concurrent high-dose stack)

The HGH + insulin "bodybuilding stack" creates severe hypoglycemia risk. HGH raises blood glucose (insulin resistance); exogenous insulin lowers it. Miscalculation can be fatal. Requires continuous glucose monitoring. Community labels this as advanced-only with experience and CGM.

Do not combine

Estimated Cost

Brand Price
Norditropin FlexPro (Novo Nordisk): ~$750 (5 mg pen) to $7,040 (15 mg pen pack) US retail, no insurance. Genotropin (Pfizer): ~$7,667 retail / ~$2,244 discounted cash price. At 1 IU/day: ~$576–$960/month at clinic rates; at 2 IU/day: ~$1,152–$1,920/month.
Compounded
No compounded price is listed. FDA says licensed biologics such as somatropin are not eligible for the 503A and 503B compounding exemptions (March 2020 notice).

Pricing updated 2026-04-09

HGH (Somatropin) Side Effects

Insulin resistance is the side effect that requires the most attention. Somatropin directly antagonizes insulin's action on glucose uptake. At doses above 2 IU daily, fasting blood glucose begins trending upward in many users. This can unmask pre-diabetes or worsen existing glycemic control. HbA1c should be checked every three to six months. Fasting glucose above 126 mg/dL is a clear signal to reduce the dose or pause the protocol.

Peripheral edema is the most common complaint by volume. Swelling in the hands and feet (peripheral edema) hit 42% of GH-deficient adults in Norditropin's 6-month trial, vs 8% on placebo. It's fluid retention, not inflammation. The body adjusts within a few weeks for most people. If pitting edema develops or swelling involves the face and neck, other causes should be investigated.

Carpal tunnel syndrome showed up in 2% of 3,031 GH-deficient adults in Genotropin's extension studies. In anti-aging trials of healthy older adults, a 2025 review puts it at 7 to 50% [3]. Fluid retention compresses the median nerve, producing wrist tingling and hand numbness. This is the most frequent reason for dose reduction in community reports. Reducing by 0.5 IU daily and holding for two to four weeks typically resolves it. Almost always reversible.

Joint pain and muscle stiffness affect roughly 20% of users, concentrated in the first few weeks. Both track with dose; both tend to settle as the body acclimates.

A 2025 review puts breast tenderness or gynecomastia at 7 to 14% in two trials of older men [3]. At doses above 4 IU daily for extended periods, some users report jaw growth and increased shoe size. These are signs of acromegaly-like effects from prolonged supraphysiological IGF-1 levels.

Cancer risk generates the most anxiety. The KIMS database (15,809 patients) found no increased malignant cancer incidence at therapeutic doses. A 2024 Swedish registry study followed 3,408 people treated as children against 50,036 matched controls for a median 19.8 years [6]. Neoplastic events overall ran higher (HR 1.28), significant in males only. Malignant tumors didn't rise (HR 0.91). Active malignancy remains a strict contraindication because GH and IGF-1 can promote tumor growth in existing cancers.

Injection site reactions (redness, mild pain) are standard for subcutaneous administration. Rotating sites prevents lipodystrophy over long-term use.

GH can unmask central hypothyroidism by increasing T4-to-T3 conversion. Monitor TSH and free T4, especially if IGF-1 levels aren't responding as expected. Hypothyroidism itself blunts the IGF-1 response.

When to seek medical attention: persistent carpal tunnel after dose reduction, fasting glucose consistently above 110 mg/dL, visible changes in facial bone structure or extremity growth, or unexplained rapid weight gain with edema.

Intracranial hypertension is a label warning that's easy to miss. Headache, vision changes, nausea or vomiting can signal it, usually within the first 8 weeks. Labels call for an eye exam before starting and periodically after, and stopping if papilledema shows up.

US label contraindications: active malignancy, active proliferative or severe non-proliferative diabetic retinopathy, and acute critical illness after major surgery, trauma or respiratory failure. Also listed: children with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. Hypersensitivity to somatropin or its excipients is on the list, as is growth use in children whose epiphyses have closed. A past cancer isn't on that list, but labels require it to be inactive and fully treated first. Pregnancy isn't either; labels say the human data are too limited to judge the risk.

Common Issues & Solutions

Carpal tunnel / wrist tingling: First sign of excess dose. Reduce by 0.5 IU/day and hold for 2–4 weeks before increasing again. Usually fully reversible. Does not require stopping protocol.

Persistent water retention beyond week 6: Consider reducing dose or switching to 5 on/2 off protocol. Avoid high-sodium foods. If edema is pitting or involves face/neck, evaluate for other causes.

Fasting glucose elevated (90–110 mg/dL range): Standard at therapeutic doses. Time injection pre-bed rather than morning to reduce postprandial impact. Add resistance training. Consider metformin if consistently above 100 mg/dL fasting.

IGF-1 not responding (stays below 150 ng/mL at 2 IU/day): Consider product quality issue, especially with grey market kits. Hypothyroidism can blunt IGF-1 response: check TSH. Oral estrogen in women significantly reduces hepatic IGF-1 output.

No noticeable effects at 8+ weeks: Verify product quality via third-party peptide testing service or serum GH test 3–4 hours post-injection. Ensure injection is truly subcutaneous (not intradermal), rotate sites, check storage against the product label (mixed vials at 2–8°C, never frozen).

Ask AI about this page

Ask AI for a second opinion on HGH (Somatropin) dosing and side effects

Contraindications

  • Active malignancy: GH and IGF-1 can promote tumor growth
  • Active proliferative or severe non-proliferative diabetic retinopathy
  • Acute critical illness (post-surgery, trauma, respiratory failure)
  • Children with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
  • Closed epiphyses in pediatric patients (for growth indication)
  • Pregnancy or breastfeeding: not a label contraindication; labels say human data are too limited to judge the risk
  • Known hypersensitivity to somatropin or excipients

Drug Interactions

  • Insulin and oral hypoglycemics: GH reduces insulin sensitivity; diabetes meds may need dose increases
  • Glucocorticoids: GH lowers cortisol activation (11β-HSD1) and can unmask adrenal insufficiency. Anyone on glucocorticoid replacement may need higher maintenance or stress doses; cortisone acetate and prednisone are affected most (US labels)
  • Oral estrogens: reduce IGF-1 response to GH; women on oral estrogen may need higher GH doses
  • CYP450 substrates (corticosteroids, sex steroids, anticonvulsants, cyclosporine): GH may alter their clearance; monitor carefully (Genotropin label)
  • Thyroid hormones: GH can unmask central hypothyroidism; monitor TSH and free T4
  • High-dose glucocorticoid therapy: can blunt somatropin's growth effect in children; adjust replacement dosing with care (US labels)
  • Somatostatin analogs (octreotide, lanreotide, pasireotide): suppress GH secretion and are used to block GH in acromegaly, so they work against HGH (community stack guidance)

Product Quality

Recommended Monitoring

TestWhenTarget
IGF-1 (serum)Baseline, then every 3 months during active protocol200–300 ng/mL for anti-aging doses; 150–400 ng/mL (age-adjusted mid-normal) for GHD treatment
Fasting blood glucoseBaseline, monthly for first 3 months, then every 3 months<100 mg/dL fasting (normal range); >126 mg/dL = dose reduction required
HbA1cBaseline, then every 3–6 months<5.7% (normal); 5.7–6.4% = caution zone; >6.5% = action required
TSH and free T4Baseline, then every 6–12 monthsTSH 0.4–4.0 mIU/L; free T4 0.9–1.7 ng/dL
Lipid panel (total cholesterol, LDL, HDL, triglycerides)Baseline, then every 6 monthsNot listed
DEXA scan (bone mineral density + body composition)Baseline, then annuallyNot listed
IGF-1 (serum)

Primary efficacy and safety marker. HGH dose-dependently raises IGF-1; supraphysiological IGF-1 associated with cancer risk and acromegaly.

Fasting blood glucose

HGH antagonizes insulin signaling; insulin resistance develops dose-dependently. Fasting glucose >100 mg/dL warrants dose adjustment.

HbA1c

Long-term glycemic impact marker. HbA1c >6.5% (diabetes threshold) in context of HGH use requires significant dose reduction or protocol pause.

TSH and free T4

GH can unmask central (secondary) hypothyroidism by increasing T4-to-T3 conversion rate. Undiagnosed hypothyroidism also blunts IGF-1 response to HGH.

Lipid panel (total cholesterol, LDL, HDL, triglycerides)

GH deficiency is associated with dyslipidemia; HGH replacement typically improves lipid profile. Monitor for unexpected adverse effects at off-label doses.

DEXA scan (bone mineral density + body composition)

Quantifies actual body recomposition (fat mass, lean mass) and bone density improvements: the primary long-term benefits of HGH therapy.

HGH (Somatropin) Before and After

Weeks 1-2

Better sleep quality is usually the first noticeable effect. Mild water retention and joint stiffness may appear as the body adjusts.

Weeks 3-6

Skin starts looking fuller and more hydrated. Energy levels improve. Recovery from workouts is noticeably faster.

Weeks 6-12

Measurable fat loss begins, especially visceral fat. Lean mass increases become apparent. Nails and hair grow faster.

Months 3-6

Significant body recomposition. Rudman's study showed 8.8% lean mass increase and 14.4% fat reduction at 6 months. Bone density may dip at first, per the Genotropin label.

Months 6-12

Full benefits realized. Bone density moves slowly: in the Genotropin label's adult trials, it dipped at 6 months and was back at baseline by 12. Lipid profile improvements stabilize. Skin elasticity at peak improvement.

What to Expect

Weeks 1 to 2 (Sleep and Water): GH begins raising IGF-1 within 24 to 48 hours of the first injection. Sleep quality is the earliest benefit most users notice, often described as deeper and more restorative with vivid dreams. Mild water retention in the hands and feet is common. Morning joint stiffness may appear. Injection site redness is typical and usually minor.

Weeks 3 to 6 (Skin and Recovery): IGF-1 reaches a new steady state around week four. Skin starts looking fuller and more hydrated. Workout recovery speeds up noticeably. Energy improves. Water retention typically stabilizes or resolves by this point. Carpal tunnel symptoms (wrist tingling, hand numbness) may surface; this is the first natural point for a dose adjustment if needed.

Weeks 6 to 12 (Recomposition Begins): Body composition changes become detectable by DEXA. Visible fat loss begins, particularly around the abdomen. Lean mass improvements become apparent. Nails and hair grow faster. Side effects are generally stable and manageable by week eight if the dose has been adjusted appropriately.

Months 3 to 6 (Peak Recomposition): This is the window where the Rudman benchmarks apply: 8.8% lean body mass gain and 14.4% fat mass reduction at the six-month mark. The 12 treated men, all over 60, got about 0.03 mg/kg three times a week. Most community users describe this as the period where results become obvious. Skin improvement peaks. Recovery speed is markedly different from baseline. Glucose management becomes the most important safety consideration; an HbA1c check is recommended at the three-month mark.

Months 6 to 12 (Bone and Metabolic Benefits): Bone density moves slowly. In the Genotropin label's adult trials, it dipped at 6 months and was back at baseline by 12. Lipid profile effects stabilize. Long-term safety data from the KIMS database is reassuring at therapeutic doses. Benefits plateau unless the dose is maintained. Most users who cycle off at six months report noticeable washout within four to eight weeks, which confirms the physiological effect rather than placebo.

Detailed Timeline: Science vs Community

Weeks 1–2
Science

GH begins elevating IGF-1 within 24–48 hours; fluid retention and insulin resistance begin at the cellular level

Community

Improved deep sleep (vivid dreams, more restorative): most consistent early effect. Mild water retention in hands and feet. Some report morning joint stiffness.

Weeks 3–6
Science

IGF-1 at new steady state by week 4; collagen synthesis and lipolysis rate changes measurable but not yet visually apparent

Community

Skin looks fuller and more hydrated. Workout recovery noticeably faster. Energy improvement. Water retention often stabilizes or resolves. Carpal tunnel may emerge: first dose-adjustment point.

Weeks 6–12
Science

Measurable changes in body composition detectable by DEXA; fat mass reduction and lean mass accrual statistically significant in 6-month trials by this stage

Community

Visible fat loss begins, especially visceral/abdominal. Lean mass improvements apparent. Nails and hair growing faster. Skin elasticity clearly improved for most users.

Months 3–6
Science

Rudman 1990 benchmarks: +8.8% lean body mass, -14.4% fat mass at 6 months (about 0.03 mg/kg three times a week). Bone density improvements begin but require 12+ months for full effect.

Community

Significant body recomposition visible. Most report this as the best period. Skin at peak improvement. Recovery speed markedly different from pre-protocol baseline.

Months 6–12
Science

In the Genotropin label's adult trials, bone density dipped at 6 months and was back at baseline by 12. Gains take longer therapy (one 6-year study: +15.9% lumbar spine at mean 2.4 IU/day). Lipid profile improvements stabilize. Long-term cancer risk data reassuring at therapeutic doses per KIMS.

Community

Benefits plateau unless dose is maintained. Most users cycle off at 6 months and report significant washout within 4–8 weeks: confirms real physiological effect rather than placebo.

Pharmacokinetics

Half-Life
3h
Bioavailability
SC: ~70-80% (US labels: Zomacton 70%, Humatrope 75%, Genotropin 80.5%); not stated for Norditropin
Tmax
3-6 hours SC
Data Confidence
high

Source: US labels, section 12.3: SC half-life 2.0 h (Norditropin, healthy adults), 2.3 h (Zomacton), 2.5-2.8 h (Omnitrope), 3.0 h (Genotropin, GHD adults), 3.8 h (Humatrope); Norditropin also gives an apparent 7-10 h in GHD patients

Pharmacokinetics: Active Dose Over Time

t½ = ~2-4 hours SC

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
191
Molecular Weight
22,124.8 Da
Sequence
FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEF
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 12629-01-5 (somatropin)

Who Should Consider HGH (Somatropin)

  • Adults with diagnosed growth hormone deficiency (AGHD)
  • Children with GHD, Turner syndrome, or idiopathic short stature
  • Adults with HIV and wasting or cachexia (Serostim label)
  • Anti-aging patients seeking improved body composition and skin quality
  • Athletes and bodybuilders (off-label, higher doses)

Related Peptides

What Changed for HGH (Somatropin)

  1. Regulatory

    Corrected Oct 15, 2026: somatropin's status section drops the 1985 date, the biosimilar claim and the kidney-disease indication, per FDA's biosimilar list.

    What this does not mean: Somatropin's FDA approval is unchanged. FDA's biosimilar list (content current Oct 5, 2026) names no somatropin, so Omnitrope is not a US biosimilar. Nutropin AQ, the kidney-disease brand, is no longer licensed.

    Source: FDA, Biosimilar Product Information (content current as of 10/05/2026): no somatropin product or somatropin reference product is listed (opens in a new tab) · Saved copy

  2. Regulatory

    Corrected Oct 15, 2026: somatropin's US status now lists its licensed BLAs and marks Saizen and Nutropin AQ revoked, per FDA's Purple Book.

    Before: No sourced US status record After: FDA-approved (licensed biologic): Norditropin BLA 021148, Genotropin BLA 020280, Humatrope BLA 019640, Omnitrope BLA 021426, Zomacton BLA 019774, Serostim BLA 020604 licensed; Saizen BLA 019764 and Nutropin AQ BLA 020522 voluntarily revoked

    What this does not mean: No approval changed. Somatropin stays a licensed biologic with the same labels; the revoked brands left the market earlier. Compounded somatropin is not a licensed product.

    Source: FDA Purple Book, monthly data download, September 2026 (BLA 021148 Norditropin, 020280 Genotropin, 019640 Humatrope, 021426 Omnitrope, 019774 Zomacton, 020604 Serostim: Rx, Licensed; 019764 Saizen and 020522 Nutropin AQ: Disc, Voluntarily Revoked) (opens in a new tab) · Saved copy

  3. Safety

    Corrected Oct 15, 2026: somatropin side effects now list the label contraindications and the intracranial hypertension warning, per the Norditropin label.

    Before: Pregnancy listed as a contraindication; no intracranial hypertension warning; edema up to 45%; carpal tunnel 1-10%; gynecomastia rare; Swedish HR 1.28 called benign-only After: Label contraindications in full, pregnancy a caution; IH warning added; edema 42% vs 8%; carpal tunnel 2% (GHD) and 7-50% (anti-aging trials); gynecomastia 7-14%; HR 1.28 all neoplasms

    What this does not mean: Not a new finding. Edema shows 42% vs 8% on placebo (Norditropin label). Carpal tunnel shows 2% in GH-deficient adults and 7-50% in anti-aging trials. HR 1.28 covers all neoplasms.

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

  4. Safety

    Corrected Oct 15, 2026: somatropin's glucocorticoid interaction now says replacement doses may need to rise, per the Norditropin label.

    Before: Glucocorticoid line twice; CYP450 examples theophylline, cyclosporine, warfarin; somatostatin said to block GH receptor signaling and fully negate HGH After: 11β-HSD1 point with higher replacement or stress doses; high-dose steroids blunt growth in children; label CYP450 examples; somatostatin analogs work against HGH

    What this does not mean: No interaction was dropped. A repeated glucocorticoid line now gives the label's pediatric growth point, and the somatostatin line loses an unsourced receptor claim.

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

  5. Safety

    Corrected Oct 15, 2026: somatropin contraindications now give the label's Prader-Willi criteria and list pregnancy as a caution, per the Norditropin label.

    Before: Prader-Willi syndrome with severe obesity or respiratory impairment (pediatric); pregnancy or breastfeeding as a contraindication, Category B/C After: Children with Prader-Willi syndrome who are severely obese or have airway obstruction, sleep apnea or severe respiratory impairment; pregnancy a label caution

    What this does not mean: Pregnancy stays on the list as a caution; labels call the human data too limited to judge. The other five contraindications are unchanged.

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

  6. Dosing

    Corrected Oct 14, 2026: somatropin's adult GHD protocol now starts at 0.15 to 0.3 mg a day, not 0.1 to 0.2 mg, per the Norditropin label.

    What this does not mean: The old range began at 0.1 mg, below the label's 0.15 mg floor, and held for 12 weeks before any step. Community dose tiers are unchanged, and the label sets no fixed maintenance dose.

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Apr 7, 202615 Citations

References

  1. [1]Effects of Human Growth Hormone in Men over 60 Years Old (Rudman et al., NEJM 1990) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Long-term Safety of Growth Hormone in Adults: Overview of 15,809 GH-Treated Patients (KIMS) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Growth hormone and aging: a clinical review (Fernandez-Garza et al., Front Aging 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Systematic review: the safety and efficacy of growth hormone in the healthy elderly (Liu et al., Ann Intern Med 2007) (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]Growth hormone replacement in healthy older men improves body composition but not functional ability (Papadakis et al., Ann Intern Med 1996) (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]Long-term risk of neoplastic events after childhood growth hormone treatment: a population-based cohort study in Sweden (Tidblad et al., Front Endocrinol 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
  7. [7]The Use and Abuse of Growth Hormone in Sports (Holt and Ho, Endocr Rev 2019) (opens in a new tab)PubMed (opens in a new tab)PubMed
  8. [8]Procollagen type III amino-terminal propeptide and insulin-like growth factor I as biomarkers of growth hormone administration (Cowan and Moncrieffe, Drug Test Anal 2022) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Resources

Related Tools

Storage & Stability

Before Reconstitution
Refrigerate at 2-8°C. Unopened vials stable 18-24 months. Avoid freezing.
After Reconstitution
Refrigerate at 2-8°C, use within 14-28 days depending on brand. Do not freeze.
Temperature
2-8°C (36-46°F). Pre-filled pens: store in fridge, use within 28 days after first use.

Frequently Asked Questions

The licensed somatropin brands (Norditropin, Genotropin, Humatrope, Omnitrope, Zomacton, Serostim) contain the same 191-amino-acid recombinant hGH. Saizen's license was voluntarily revoked, per FDA's Purple Book. Differences are delivery device, formulation (liquid vs lyophilized), and cost. Omnitrope (Sandoz) is often called a biosimilar, but FDA's biosimilar list includes no somatropin product.

FDA-labeled adult GHD replacement: start at 0.15-0.3 mg daily (roughly 0.5-1 IU), titrate based on IGF-1 levels. Community anti-aging protocols run 1-2 IU daily. Performance doses range from 3-6 IU daily. Always start low; side effects scale directly with dose.

Brand-name Norditropin or Genotropin runs roughly $1,200-2,000 per month retail at 2 IU/day. Omnitrope runs $800-1,200/month at a discounted cash price. No compounded price is listed, since FDA says licensed biologics such as somatropin are not eligible for the 503A or 503B compounding exemptions. Insurance coverage requires documented GH deficiency.

IGF-1 is the primary marker: check at baseline, 4 weeks, and every 3 months. Target is upper-normal for age. Fasting glucose and HbA1c every 3-6 months to catch insulin resistance. Lipid panel annually. PSA for men over 40. Watch for IGF-1 exceeding the reference range, as supraphysiological levels carry long-term risk.

The FDA label supports long-term use for diagnosed GH deficiency. The KIMS database (Pfizer) followed 15,809 adults with GH deficiency for a mean 5.3 years, with a favorable safety profile (PMID 35368070). Concerns center on insulin resistance, cancer risk from sustained IGF-1 elevation, and carpal tunnel. Dose matters: replacement-level dosing (1-2 IU) carries far less risk than performance dosing (4-8 IU).